CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Atopic Dermatitis
- Friday, October 16, 2020, 7:14
- PR Newswire
- Add a comment
TARRYTOWN, N.Y. and PARIS, Oct. 16, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Dupixent® (dupilumab),…
About the Author
admin has written 21728 stories on this site.